Schizophrenia is a devastating mental illness characterized by symptoms eg hallucinations, disorganized thinking, loss of goal-directed behaviors and deterioration in social role functioning.
Positive or psychotic symptoms are delusions, hallucinations, and distorted perceptions.
Negative symptoms include flat or blunted emotions, lack of motivation or energy, lack of pleasure or interest in things, and limited speech.
Disorganized symptoms are confused thinking, disorganized speech and behavior.
Cognitive symptoms include impairment in attention verbal fluency memory, and executive functioning.
Patients with schizophrenia, regardless of medication, exhibit pervasive deficits in cognitive function, including the domains of reinforcement learning, processing speed, cognitive control, working memory, verbal learning, and relational encoding and retrieval, a study has shown.
Chronic schizophrenia patients receiving long‐acting injectable antipsychotics (LAIAs) have more favourable outcomes than those receiving oral antipsychotics in the maintenance setting, with LAIAs tied to a lower risk of disease relapse and a reduction in psychiatric service utilization, as shown in a study.
Duration of untreated psychosis (DUP) is associated with psychosocial function, but it appears to be only an “artifact” of early detection, suggests a recent study. Such association creates the impression that early intervention can lead to improved outcomes.
New drug applications approved by US FDA as of 16 - 31 December 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Several anti-inflammatory drugs, including aspirin, oestrogens, minocycline and N-acetylcysteine, appear to help mitigate symptom severity in patients with schizophrenia, according to a systematic review and meta-analysis.
Continuous primary care follow-up during the transition from adolescence to young adulthood could reduce the risk of mental illness-related hospitalizations post-transition in individuals with severe mental illness, according to a Canadian study.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.